Retinal OCTA to detect tiny blood vessel problems in people with MINOCA
Official title: Retinal OCTA for Microvascular Dysfunction Evaluation and Outcome Prediction in MINOCA Patients
Run by University of Pisa · NCT07055152 · Data updated 2026-11-12
This project will use a quick retinal OCTA scan to see if tiny blood vessel changes differ in people with MINOCA compared with heart attack patients who have blocked arteries and with healthy volunteers.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 90 (estimated) |
| Sponsor | University of Pisa Academic / other |
| Locations | 1 site (Pisa, Pisa) |
| Status | Recruiting |
| Started | January 1, 2025 |
| Main results expected | January 1, 2026 |
| Study ends | January 1, 2027 |
| Registry record updated | July 8, 2025 |
| Trial ID | NCT07055152 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults over 18 with confirmed MINOCA by coronary angiography, matched ACS patients, and age- and sex-matched healthy volunteers who can undergo OCTA and give written informed consent are suitable.
✕Probably not a fit
People with significant eye disease that prevents good OCTA imaging or with severe systemic illnesses that preclude participation are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study will use optical coherence tomography angiography (OCTA) of the retina to compare microvascular parameters across three matched groups: patients with MINOCA, patients with acute coronary syndrome (ACS) with obstructive coronary disease, and healthy controls. Matching will be done for age, sex, left ventricular ejection fraction at admission, and chronic kidney disease stage to reduce confounding. Within the MINOCA group the study will look for differences between clinical subtypes (for example Takotsubo syndrome, vasospastic angina, microvascular angina, and cases with plaque erosion) to explore possible mechanisms. Retinal microvascular metrics will be analyzed to see whether they differ between groups and whether they predict outcomes in MINOCA patients.
Why it matters
Potential benefit: If successful, a noninvasive retinal OCTA scan could help identify microvascular dysfunction and provide a biomarker to stratify risk or guide follow-up in MINOCA patients.
How similar studies have gone: Prior research has linked retinal microvascular changes on OCTA to coronary and microvascular disease, but applying OCTA specifically to compare MINOCA subtypes is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age: Patients aged \> 18. Diagnosis: MINOCA Group: Patients diagnosed with Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA) confirmed by coronary angiography. ACS Group: Patients with Acute Coronary Syndrome (ACS) with significant coronary artery stenosis which are matched with MINOCA patients for gender, age, LVEF at admission and chronic kidney disease stage. Healthy Controls: Age and gender-matched healthy individuals with no history of cardiovascular disease. Consent: Written informed consent obtained from all participants. Feasibility: Ability to undergo OCTA and other required imaging procedures. Exclusion Criteria: * Ocular Conditions: Any significant ocular disease (e.g., glaucoma, diabetic retinopathy, macular degeneration) that could interfere with OCTA imaging quality. Severe Comorbidities: Presence of severe systemic diseases, such as advanced renal failure, active cancer, or severe liver disease, which might impact study participation. Coronary Artery Disease or Myocarditis: For the MINOCA group, patients with coronary artery stenosis \> 50% or functionally significant (FFR \<0.8) or patients with Myocarditis detected through CMR will be excluded Pregnancy: Pregnant or breastfeeding women. Inability to Comply: Patients unable or unwilling to comply with study procedures, including follow-up visits.
Where it's running
-
University of Pisa, Cisanello Hospital
Pisa, Pisa, Italy Recruiting
Study contacts
- Study coordinator: Mattia Alberti, Dr
- Email: mattia.alberti96@outlook.it
- Phone: +393271946335
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Early single antiplatelet therapy after IVUS-guided PCI in ACS
This study tests whether stopping aspirin early and continuing a potent P2Y12 inhibitor alone is safe and effective after IVUS-guided PCI in people with acute coronary syndrome.
-
Drug-coated balloon treatment during emergency angioplasty for STEMI
This registry will try using drug-coated balloons instead of stents during emergency PCI for people with ST-elevation heart attacks to see how the procedure and patient outcomes compare.
-
Early intravenous landiolol to limit heart muscle damage after STEMI
This study tries early IV landiolol versus standard oral beta-blockers to see if it reduces the amount of heart muscle damage in adults with STEMI who undergo primary PCI.
-
High-intensity interval training and causes of low cardiorespiratory fitness in people with ANOCA
This project will test whether a four-week remotely monitored high-intensity interval training (HIIT) program can safely improve fitness, heart function, and quality of life for adults with angina but no obstructive coronary artery disease (ANOCA).
-
Comprehensive coronary physiology testing for adults with angina but no blocked coronary arteries in the Czech Republic
This project will test detailed invasive coronary physiology and vasospasm tests in adults who have angina but no major coronary blockages to see if microvascular dysfunction or spasms explain their symptoms.
-
Long-term changes in left ventricular function after STEMI
We will test whether detailed heart imaging and blood tests can track long-term changes in heart structure and function in people who had a STEMI treated with primary PCI.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.